1 2	Glycolysis-enhancing α_1 -adrenergic antagonists modify cognitive symptoms related to Parkinson's disease
3 1	
5 6 7	Matthew A. Weber, PhD ^{#,*,1} , Kartik Sivakumar ^{*,1} , Ervina E. Tabakovic ¹ , Mayu Oya ¹ , Georgina M. Aldridge, MD, PhD ¹ , Qiang Zhang, MD ¹ , Jacob E. Simmering, PhD ² , Nandakumar S. Narayanan, MD, PhD ^{#,1}
8	
9	Affiliations:
10 11	¹ Department of Neurology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City.
12	
13 14	² Department of Internal Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City.
15	
16	
17 18 10	faculty fellowship through the Iowa Neuroscience Institute to JES and NIH R01s MH116043, NS120987 to NSN
20	
21	Conflict of Interest:
22	There are no conflicts of interest.
23	
24	
25	Abstract: 175
26	Main Text: 3831
27	Figures: 4
28	Tables: S1
29	
30	
31	*These authors contributed equally to this manuscript as co-first authors.
32 33	# Corresponding Author
34	Matthew A. Weber
35	matthew-weber@uiowa.edu
36	169 Newton Road
37 38	Pappajohn Biomedical Discovery Building—5326 University of Iowa, Iowa City, 52242

39 Abstract

40	Terazosin is an α_1 -adrenergic receptor antagonist that enhances glycolysis and increases cellular ATP by
41	binding to the enzyme phosphoglycerate kinase 1 (PGK1). Recent work has shown that terazosin is
42	protective against motor dysfunction in rodent models of Parkinson's disease (PD) and is associated with
43	slowed motor symptom progression in PD patients. However, PD is also characterized by profound
44	cognitive symptoms. We tested the hypothesis that terazosin protects against cognitive symptoms
45	associated with PD. We report two main results. First, in rodents with ventral tegmental area (VTA)
46	dopamine depletion modeling aspects of PD-related cognitive dysfunction, we found that terazosin
47	preserved cognitive function and produced a non-statistically significant trend towards protected VTA
48	tyrosine hydroxylase levels. Second, we found that after matching for demographics, comorbidities, and
49	disease duration, PD patients newly started on terazosin, alfuzosin, or doxazosin had a lower hazard of
50	being diagnosed with dementia compared to tamsulosin, an α_1 -adrenergic receptor antagonist that does
51	not enhance glycolysis. Together, these findings suggest that in addition to slowing motor symptom
52	progression, glycolysis-enhancing drugs protect against cognitive symptoms of PD.

53 INTRODUCTION

54	Parkinson's disease (PD) is a devastating neurodegenerative disease with motor and cognitive
55	symptoms (Dauer & Przedborski, 2003). A key risk factor for PD is impaired energy metabolism
56	(Saxena, 2012; Wellstead & Cloutier, 2011). We have recently found that the glycolysis-enhancing drug
57	terazosin increases energy metabolism in rodent models and in PD patients (Cai et al., 2019; Schultz et
58	al., 2022). We have also found that terazosin protects against motor neurodegeneration in the MPTP (1-
59	methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model, the 6-hydroxydopamine (6-OHDA) rat model,
60	as well as synuclein-overexpressing mice (Cai et al., 2019). Strikingly, analysis of the Progression
61	Markers Initiative (PPMI) database shows that terazosin is also associated with slowed motor symptom
62	progression in human PD patients (Cai et al., 2019). Furthermore, based on data from large administrative
63	databases, it protects against developing PD (Sasane et al., 2021; Simmering et al., 2021). Notably,
64	patients taking terazosin had fewer cognitive complications, as indexed by International Classification of
65	Diseases (ICD) codes (Cai et al., 2019). Despite these data, it is unclear whether terazosin is
66	neuroprotective for cognitive manifestations of PD.
67	One challenge is that there are few rodent models of cognitive dysfunction in PD. Human
68	cognition is complex and spans multiple behavioral repertoires such as planning and reasoning, which are
69	challenging to model in rodents. We have found that PD patients with cognitive dysfunction have
70	increased variability during interval timing, which involves estimating an interval of several seconds
71	(Parker et al., 2015; Singh et al., 2021). Specifically, PD patients with cognitive dysfunction have higher
72	interval timing variability compared to PD patients with preserved cognitive function. Because interval
73	timing can be readily studied in rodents (Buhusi & Meck, 2005), and work from our group has
74	demonstrated that interval timing is reliably impaired with disrupted ventral tegmental area (VTA)
75	dopamine (Kim et al., 2017; Kim & Narayanan, 2018; Narayanan et al., 2012; Parker et al., 2015),
76	interval timing provides an opportunity to investigate cognitive deficits in PD rodent models as a function
77	of terazosin.

78	In this study, we tested the hypothesis that terazosin protects against cognitive symptoms
79	associated with PD. We found that rodents with VTA dopamine depletion via 6-OHDA injections had
80	higher interval timing variability, similar to PD patients with cognitive dysfunction. Subsequently, we
81	found that mice receiving daily terazosin delivered in drinking water had decreased interval timing
82	variability and marginally more tyrosine hydroxylase-positive (TH+) immunofluorescence in the VTA.
83	Since terazosin is prescribed to human PD patients, we were able to combine these results with an
84	investigation of the association between clinically prescribed terazosin and cognitive symptoms in PD in
85	the IBM Marketscan administrative database. We found that human PD patients taking terazosin or
86	related glycolysis-enhancing medications had less risk of developing dementia compared to propensity-
87	score-matched patients taking tamsulosin, an α_1 -adrenergic receptor antagonist that does not enhance
88	glycolysis. Together, these data provide evidence that terazosin protects against cognitive symptoms, as
89	well as motor symptoms, associated with PD.

91 **RESULTS**

92 VTA 6-OHDA increases interval timing variability

We trained 29 mice starting at $\sim 14-16$ weeks of age to perform an interval timing task in which 93 mice switched from one nosepoke to another based on internal timing cues to get a food reward (Fig. 1A; 94 95 Balci et al., 2008; Bruce et al., 2021; Larson et al., 2022). In these animals, we surgically injected vehicle 96 (0.03% ascorbic acid) as a surgical control or 6-OHDA to deplete dopamine in the VTA, which we have 97 previously shown impairs interval timing (Kim et al., 2017; Narayanan et al., 2012; Parker et al., 2015). 98 We began treatment with terazosin or vehicle (dimethyl sulfoxide; DMSO) immediately and tested 99 performance in the interval timing switch task approximately 16 days post-surgery. We normalized postsurgical behavior in the switch task to pre-surgery behavior to determine magnitude change in behavior as 100 101 a result of VTA dopamine depletion and terazosin treatment. In VTA 6-OHDA mice treated with vehicle, 102 we found no significant change in median switch time (Vehicle DMSO: 103% (93%-117%; relative to 103 presurgical baseline) vs 6-OHDA DMSO: 92% (83%-105%); Wilcoxon p = 0.12; Cohen's d = 0.66), but 104 increased timing variability as measured by the coefficient of variability (CV) relative to Vehicle DMSO 105 controls (Vehicle DMSO: 93% (86%–104%) vs 6-OHDA DMSO: 118% (116%–123%); Wilcoxon p < p0.05; Cohen's d = 1.66; Fig. 2B–C). There were no changes in the number of switch trials performed 106 107 (Vehicle DMSO: 30 (18–44) vs 6-OHDA DMSO: 38 (30–45); Wilcoxon p = 0.60; Cohen's d = 0.23, data 108 not shown) or total number of rewards obtained during short and switch trials (Vehicle DMSO: 102 (95-109 124) vs 6-OHDA DMSO: 106 (88–155); Wilcoxon p = 0.96; Cohen's d = 0.27, data not shown). These 110 results were similar to the increased interval timing CV observed in PD patients associated with cognitive 111 dysfunction (Singh et al., 2020) and provide evidence that VTA dopamine depletion models aspects of cognitive dysfunction in human PD patients. 112

113

114 Terazosin protects against VTA 6-OHDA timing deficits.

115 Terazosin is neuroprotective in preclinical rodent models of PD-related motor dysfunction (Cai et
116 al., 2019). We investigated whether terazosin protects against the effects of VTA 6-OHDA in interval

117	timing. Strikingly, we found that VTA dopamine-depleted mice treated with terazosin had decreased
118	interval timing variability relative to VTA 6-OHDA mice treated with vehicle (6-OHDA DMSO: 118%
119	(116%-123%) vs 6-OHDA terazosin: 97% (88%-108%); Wilcoxon $p < 0.05$; Cohen's $d = 1.53$), but no
120	change in median switch time (6-OHDA DMSO: 92% (83%-105%) vs 6-OHDA terazosin: 101% (92%-
121	106%); Wilcoxon $p = 0.40$; Cohen's $d = 0.35$; Fig. 2a–c). There were no changes in the number of switch
122	trials performed (6-OHDA DMSO: 38 (30–45) vs 6-OHDA terazosin: 25 (16–51); Wilcoxon $p = 0.68$;
123	Cohen's $d = 0.09$, data not shown) or total number of rewards obtained during short and switch trials (6-
124	OHDA DMSO: 106 (88–155) vs 6-OHDA terazosin: 113 (97–128); Wilcoxon <i>p</i> = 1.0; Cohen's <i>d</i> = 0.07,
125	data not shown). These data support our hypothesis that terazosin is protective in rodents modeling
126	aspects of cognitive dysfunction in PD.
127	We also examined the levels of TH+ immunofluorescence in the VTA as an indirect measure of
128	dopamine depletion (Fig. 3a), since terazosin has been shown to protect substantia nigra TH levels in rats
129	(Cai et al., 2019) VTA 6-OHDA mice had markedly decreased TH+ fluorescence in the VTA (Vehicle
130	DMSO: 1776 (1577–2010) arbitrary units (AU) vs 6-OHDA DMSO: 673 (623–779) AU; Wilcoxon p <
131	0.05; Cohen's $d = 3.07$; Fig. 3b). Interestingly, we found a non-statistically significant trend for increased
132	TH+ fluorescence in the VTA of dopamine-depleted mice treated with terazosin relative to DMSO (6-
133	OHDA DMSO: 673 (623–779) vs 6-OHDA terazosin: 1071 (653–1094); Wilcoxon <i>p</i> = 0.09; Cohen's <i>d</i> =
134	0.79; Fig. 3b), suggesting that terazosin tended to protect TH+ neurons in the VTA of dopamine-depleted
135	mice. This effect of terazosin is similar to that observed previously (Cai et al., 2019). To establish a
136	relationship between the change in VTA TH+ immunofluorescence and behavioral results, we correlated
137	fluorescence values with changes in switch time CV following surgery and DMSO or terazosin treatment.
138	We observed that VTA TH+ fluorescence in all DMSO-treated mice had a strong and significant negative
139	correlation with changes in switch time CV, such that greater VTA TH+ fluorescence values were related
140	to lower switch time CV ($r = -0.59$; $p < 0.05$); there was also a similar non-significant relationship
141	between switch time CV and VTA TH+ fluorescence values in dopamine-depleted mice treated with
142	terazosin ($r = -0.47$; $p = 0.15$; Fig. 3c).

143

144 TZ protects against cognitive symptoms of PD

- 145 An analysis of patient databases was used to determine whether glycolysis-enhancing terazosin,
- 146 alfuzosin, or doxazosin (TZ/AZ/DZ) is associated with lower hazard of developing dementia compared to
- tamsulosin. We identified 14,184 men with PD who had not taken TZ/DZ/AZ or tamsulosin previously.
- 148 After matching for demographics, comorbidities, and disease duration, 1508 men (754 matched pairs)
- remained. This matching successfully reduced imbalance between the groups (Supplemental Table S1).
- After matching, the reduction was a statistically significant 25% reduction (HR = 0.75; 95% CI: 0.57,
- 151 0.98) in the hazard of being diagnosed with dementia (Fig. 4).

153 **DISCUSSION**

154 We tested the hypothesis that the glycolysis-enhancing drug terazosin is protective against cognitive dysfunction associated with PD. We found that VTA dopamine-depleted mice had increased 155 156 interval timing variability, modeling cognitive deficits seen in PD patients. Rodents with VTA dopamine 157 depletion and terazosin had preserved interval timing variability and a trend toward more VTA TH+ 158 fluorescence compared to dopamine-depleted mice treated with vehicle. Finally, analysis of patient 159 databases revealed that PD patients newly started on terazosin had less risk of developing dementia 160 compared to PD patients taking tamsulosin, an α_1 -adrenergic receptor antagonist that does not impact 161 glycolysis. Together these data provide evidence that terazosin is protective for cognitive, as well as 162 motor, symptoms of PD. This is key as there are only a few minimally effective treatments for PD-related 163 cognitive symptoms and no treatments that alter disease course.

164 Increased interval timing variability models some aspects of cognitive dysfunction in PD and 165 Alzheimer's disease patients (Gür et al., 2020; Kim et al., 2017; Larson et al., 2022; Parker et al., 2015; 166 Singh et al., 2021). Importantly, the VTA is involved in PD and degenerates through the course of the 167 disease (Alberico et al., 2015). Accordingly, we observed that VTA dopamine depletion increased interval timing variability, and terazosin reversed or prevented deficits. Furthermore, we found a non-168 169 statistically significant trend for more TH+ fluorescence in VTA dopamine-depleted mice treated with 170 terazosin compared to those treated with DMSO alone. The level of VTA TH+ fluorescence correlates with interval timing variability (Gür et al., 2020). However, this correlation does not hold for VTA 171 172 dopamine-depleted treated with terazosin as this treatment likely changed the relationship between VTA 173 TH+ fluorescence and interval timing variability. Further, it is possible that terazosin might increase 174 synaptic dopamine in the projection fields of VTA dopamine neurons, as was observed in nigrostriatal 175 dopamine terminals (Cai et al., 2019). Our data establish that VTA dopamine depletion models PD-like 176 increased interval timing variability, which is protected by terazosin.

From analysis of patient databases, we previously showed that terazosin is associated with fewer
PD diagnostic codes linked with cognition, relative to tamsulosin (Cai et al., 2019). Here, we expand this

finding and show that PD patients have less risk of developing dementia relative to patients taking 180 tamsulosin. Because these data are derived from large administrative databases, it is difficult to discern 181 whether these patients had interval timing deficits. Our work has several limitations. First, there is no definitive rodent model of cognitive 182 183 dysfunction in PD, in part because the underlying pathophysiology is complex and diverse. However, our 184 model of VTA dopamine depletion models at least one characteristic of cognitive dysfunction in PD. 185 Second, the mechanistic link between enhanced glycolysis and protection of dopamine neurons, dopamine 186 release, or TH levels and/or production is unclear. However, it is possible that terazosin is protecting 187 against VTA 6-OHDA-induced cell death or enhancing TH or dopamine similar to that observed in the nigrostriatal pathway (Cai et al., 2019). This is an important future direction to understand how 188 189 glycolysis-enhancing therapeutics can modulate neurodegenerative disease. Third, our data from terazosin 190 are retrospectively observational and depend on comparisons with tamsulosin (Gros et al., 2021; Sasane et 191 al., 2021; Simmering et al., 2021). 192 These data converge with our prior work on motor symptoms of PD and provide evidence that 193 terazosin is protective not only for neurons in the substantia nigra, but also in the ventral tegmental area 194 (Alberico et al., 2015; Cai et al., 2019). Future studies will rigorously test this idea with a prospective and

196 and with cellular, molecular, and preclinical studies to understand how enhancing glycolysis modulates

placebo-controlled randomized trial, in which motor and cognitive aspects of PD are carefully measured,

197 brain circuits.

198

195

199 MATERIALS AND METHODS

200 Mice: All experimental procedures were performed in accordance with the relevant guidelines of Protocol #0062039 and with the approval of the Institutional Animal Care and Use Committee (IACUC) 201 202 at the University of Iowa. Wild-type male and female C57BL/6 mice were received from Jackson Labs 203 (Bar Harbor, ME) at approximately 12–14 weeks of age and acclimated to the animal holding facility for 204 2 weeks. During acclimation, all mice were communally housed on a 12-hour light/dark cycle with ad lib 205 access to laboratory rodent chow and water. To facilitate operant behavioral training (described below), 206 mice were individually housed, weighed daily, and maintained on a restricted diet with *ad lib* access to 207 water.

208

Interval Timing Switch Task: The interval timing switch task is designed to capture an animal's internal representation of time (Balci et al., 2008; Bruce et al., 2021; Larson et al., 2022; Tosun et al., 2016), as in other interval timing tasks (Emmons et al., 2020; Narayanan et al., 2012). Mice are trained to switch from a short to a long nosepoke after approximately 6 seconds. This switch is an explicit time-based decision that requires working memory for temporal rules and attention to the passage of time, and models cognitive deficits in neurodegenerative disease (Gür et al., 2020; Larson et al., 2022; Parker et al., 2015; Singh et al., 2021).

Briefly, mice were trained in standard operant chambers enclosed in sound-attenuated cabinets 216 (MedAssociates, St. Albans, VT) that contained two light-equipped nosepoke response ports (left and 217 218 right) on the front wall, a reward hopper located between the two nosepoke response ports, and another 219 light-equipped nosepoke on the back wall, opposite the reward hopper. Operant training began by shaping 220 the animal's behavior. Trial initiation began with a response at the back nosepoke, at which point either 221 the left or right front nosepoke was illuminated, and a response at the appropriate port resulted in a 222 reward. Mice were then advanced to the interval timing switch protocol, in which each session was 223 randomly organized into 50% short (6 seconds) and 50% long (18 seconds) trials. Either the left or right 224 nosepoke was designated for short trials and the contralateral nosepoke for long trials (counterbalanced

225 across experimental groups). A back nosepoke response initiated a trial, generating two identical light 226 cues above the left and right nosepokes, along with an 8-kHz tone (72 dB) for both trial types. In short 227 trials mice received a reward after 6 seconds for the first response at the designated nosepoke. In long 228 trials, mice would begin by responding at the short-trial-designated nosepoke. When there was no 229 reinforcement after 6 seconds, the mouse would switch to the long-trial-designated nosepoke until a 230 reward was delivered after 18 seconds. Once mice were performing optimally, they were taken off food 231 restriction and underwent stereotaxic surgical procedures (outlined below). Behavioral changes were 232 assessed by retraining the mice in the same interval timing switch task. Only long switch trials were 233 analyzed during both training periods.

234

Surgical Procedures: On the day of surgery, 6-hydroxydopamine hydrobromide (6-OHDA; 235 236 Millipore Sigma #162957, Darmstadt, Germany) and desipramine hydrochloride (Millipore Sigma #D3900) were freshly made and stored on ice away from light. 6-OHDA was prepared at 2 mg/ml in 237 238 0.03% ascorbic acid (AA) and designamine at 4 mg/ml in 0.9% saline. Mice were anesthetized under 239 4.0% isoflurane at 400 ml/min, and surgical levels of isoflurane (1.5% - 3.0%) were maintained at 240 approximately 120 ml/min (SomnoSuite, Kent Scientific, Torrington, CT, USA). Desipramine (25 mg/kg) 241 was injected intraperitoneally (IP) to protect norepinephrine terminals against 6-OHDA (Thiele et al., 2012; Torres & Dunnett, 2012). An incision was made along midline and bilateral craniotomies drilled 242 243 above the VTA (AP -3.3, ML +/-1.1). Mice were randomly assigned to three different groups: 1) 244 midbrain vehicle injections treated with dimethyl sulfoxide (DMSO; Vehicle DMSO); 2) VTA dopamine 245 depletion treated with DMSO (6-OHDA DMSO); and 3) VTA dopamine depletion treated with terazosin (6-OHDA terazosin). The vehicle group received microinjections of 0.5 µl 0.03% AA bilaterally, and the 246 247 dopamine-depletion groups received equal volumes of 6-OHDA prepared in AA (AP -3.3, ML +/-1.1, DV 248 -4.6 at 10° laterally). Vehicle or 6-OHDA was infused over 10 minutes (0.05 µl/min; Legato 130 Syringe 249 Pump, kd Scientific, Holliston, MA, USA), with a 5-minute wait period before removing the needle. After 250 the incision was closed, mice were moved to a clean cage with *ad lib* access to food and either DMSO- or

terazosin-treated water (described below). All mice recovered for one week before transitioning back to
the interval timing switch task for approximately 3–4 weeks of post-surgical behavioral training.

253

254 Mouse terazosin: Following surgery, terazosin (Tocris #1506, Minneapolis, MN) prepared in 255 DMSO was delivered through ad lib access to treated water. Water for control mice was made with 256 equivalent volumes of DMSO alone. Preparation of terazosin began with a 100-mM stock solution (42 mg/ml in DMSO) stored at -80 °C. The stock was diluted 1:100 to make a 1-mM (0.42 µg/µl in water) 257 258 working solution. We added 106 μ L of working solution, equating to 45 μ g terazosin (0.42 μ g/ μ l x 106 259 ul), to 300 ml water, to which mice had free access. The concentration of the final drinking water was 260 $0.15 \,\mu$ g/ml terazosin (45 μ g/300 ml). An average mouse drinks approximately 5 ml of water per day 261 (Nicolaus et al., 2016), so each mouse consumed ~ $0.75 \,\mu g$ terazosin daily (0.15 $\mu g/ml \ge 5 \,ml/day$). 262 Additionally, experimental mice weigh on average 0.025 kg (Nicolaus et al., 2016); thus, the terazosin dose received by our animals was ~0.03 mg/kg/day (0.75 µg/day/0.025 kg). All terazosin- and DMSO-263 264 treated water was replaced every 2 days for the duration of the experiment post-surgery (Cai et al., 2019). 265

266 **Histology:** Mice were anesthetized with ketamine (100 mg/kg IP) and xylazine (10 mg/kg IP) and 267 transcardially perfused with cold phosphate-buffered saline (PBS) and 4% paraformaldehyde (PFA). 268 Brains were removed and post-fixed in 4% PFA overnight, followed by immersion in 30% sucrose for 269 approximately 48 hours. The fixed brains were sliced at 40- μ m coronal sections of the midbrain, using a 270 cryostat (Leica Biosystems, Deer Park, IL). Sections were then blocked for one hour in 5% normal goat 271 serum (NGS) in PBST (0.3% Triton X-100 in 1x PBS). After blocking, sections were incubated overnight 272 at 4 °C in rabbit anti-tyrosine hydroxylase polyclonal antibody (Abcam #ab6211, Cambridge, UK) diluted 273 to 1:1000 in 5% NGS. The sections were washed with PBST three times over 30 minutes before a 2-hour 274 incubation in goat anti-rabbit IgG (H+L) Alexa Fluor 568 secondary antibody (Invitrogen #A-11036, 275 Waltham, MA) diluted to 1:1000 in 5% NGS. After three more PBST washes, the sections were mounted

with ProLong Diamond Antifade Mountant with DAPI (Invitrogen #P36962) on Superfrost microscope
slides (Fisher Scientific, Waltham, MA).

Brain sections were imaged using an Olympus VS120 microscope (Olympus, Center Valley, PA). 278 279 Histological targeting of the VTA was confirmed by two independent authors, one blinded to treatment 280 conditions. Eight mice, in which the injection missed the VTA, were excluded. For the remaining mice, 281 the Count and Measure analysis tool in CellSens Dimension Desktop (Olympus, Shinjuku, Tokyo, Japan) 282 was used to quantify tyrosine hydroxylase (TH) fluorescence levels in the VTA. Fluorescence levels in 283 each animal were determined by averaging the mean pixel intensities of three VTA sections. Anterior-284 posterior coordinates of the VTA were determined following prior literature and ranged from -3.1 to -3.5, 285 respectively. Outlines of the regions of interest were referenced from Franklin & Paxinos, 2008. 286 287 Statistics: We analyzed effects of dopamine depletion and terazosin using a generalized linear 288 model (*lm* in R). Post-hoc comparisons were performed using estimated marginal means (*emmeans* in R) 289 and Tukey's correction for multiple comparisons. Four-to-five sessions of interval timing behavior were 290 collected and analyzed per mouse, both before surgery and approximately 16 days post-surgery. Switch

time coefficients of variability (CV) and mean switch times were normalized to each mouse's pre-surgical
baseline to account for animal-specific variability in timing behavior. All statistics was reviewed by the
Biomedical Epidemiology Research and Design core in the Institute for Clinical and Translational
Sciences at the University of Iowa.

295

Administrative Database Search: Using the IBM Marketscan Commercial Claims and Encounters and the Medicare Coordination of Benefits databases of health insurance claims, we identified men aged 40 or older taking terazosin, alfuzosin, or doxazosin (collectively, TZ/DZ/AZ) or tamsulosin, not in conjunction with finasteride or dutasteride. Men who switched between the TZ/DZ/AZ and tamsulosin classes were excluded. To ensure that we identified men who were newly started on TZ/DZ/AZ or Tamsulosin, we required: 1) at least 12 months of enrollment prior to the observed first

302	dispensing date with prescription drug coverage; 2) at least two dispensing events to occur in the first year
303	following the first dispensing date; 3) the PD diagnosis date must have occurred before the TZ/DZ/AZ or
304	tamsulosin start date; and 4) the men must have been free of a dementia diagnosis (ICD-9-CM: 289.9,
305	290.0, 290.1, 290.2, 290.3, 290.4, 290.43, 294.1, 294.8, 331.0, 331.1, 348.3 or ICD-10-CM: F01.51,
306	F03.90, F05, F06.0, F06.8, F29) at start of medication. To ensure that we identified new cases of PD, the
307	first observed diagnosis of PD or dispensing of levodopa must have occurred within at least 12 months of
308	TZ/DZ/AZ or tamsulosin start date; health insurance claims data do not include detailed measures of PD
309	severity, e.g., Unified Parkinson's Disease Rating Scale scores or cognitive function. The administrative
310	database search and subsequent analysis described below was performed on a fully deidentified secondary
311	database and was therefore exempt from institutional review board approval.

312

313 Administrative Database Analysis: Men taking TZ/DZ/AZ were matched to men taking 314 tamsulosin in a two-stage process. First, we estimated a propensity score model incorporating the 315 following criteria: age; health care utilization during the lookback period (rate of hospitalization, rate of 316 outpatient encounters); baseline health status (mean number of diagnoses per outpatient encounter, rate of 317 unique outpatient diagnoses, the 29 Elixhauser comorbidities); factors for prescribing decision (diagnosis 318 of benign prostatic hyperplasia, diagnosis of slow urinary stream, diagnosis of abnormal prostate-specific 319 antigen (PSA), diagnosis of orthostatic hypotension, diagnosis of other hypotension, procedural claim for 320 testing PSA, procedural claim for a uroflow study, procedural claim for a cystometrogram); and 321 medication start date. The propensity score model was estimated using a boosted tree with the depth and 322 number of rounds selected by testing performance on a 25% held-out validation set. Once the depth and 323 number of rounds were selected, we used the entire data set to generate and estimate the propensity score 324 model. Second, we required the time between the diagnosis of PD and the medication start date to be +/-325 180 days between possible matches. This was done to ensure a similar duration of disease and to 326 potentially reduce unobserved heterogeneity due to differing PD severity. Within the set of possible 327 matches based on the time between PD diagnosis and the medication start date, we selected the nearest

- possible match based on the log odds estimated by our propensity score model. We imposed a 20%
- 329 pooled standard deviation caliper to exclude poor matches. After matching, we followed the medical
- records of men for 8 years to track the rates of developing dementia. We compared the hazard of
- developing dementia with Kaplan Meier survival curves and Cox proportional hazards regression.
- 332 Standard errors were clustered to account for the propensity score matching.

333 ACKNOWLEDGEMENTS

334	The Truven database was provided by the University of Iowa. This work was supported by a
335	faculty fellowship through the Iowa Neuroscience Institute to JES and NIH R01s MH116043, NS120987
336	to NSN.
337	
338	DATA AVAILABILITY
339	All code and raw data are available at <u>https://narayanan.lab.uiowa.edu</u> .
340	
341	AUTHOR CONTRIBUTIONS
342	MAW, KS, and NSN designed the animal experiments. JES and NSN designed the human PD
343	database analysis. MAW, KS, and MO performed all animal experiments. MAW and KS independently
344	verified histological targeting. EET, KS, and GMA performed histological immunofluorescent analysis.
345	MAW, KS, and QZ maintained and delivered terazosin. MAW, KS, JES, and NSN performed all
346	statistical analyses. MAW, KS, JES and NSN wrote the manuscript, and all authors reviewed and revised
347	the manuscript.
348	
349	COMPETING INTERESTS

350 The authors declare that there are no conflicts of interest.

351 **REFERENCES**

- Alberico, S. L., Cassell, M. D., & Narayanan, N. S. (2015). The vulnerable ventral tegmental area in
- 353 Parkinson's disease. *Basal Ganglia*, 5(2–3), 51–55. https://doi.org/10.1016/j.baga.2015.06.001
- Balci, F., Papachristos, E. B., Gallistel, C. R., Brunner, D., Gibson, J., & Shumyatsky, G. P. (2008).
- 355 Interval timing in genetically modified mice: A simple paradigm. *Genes, Brain and Behavior*,
- 356 7(3), 373–384. https://doi.org/10.1111/j.1601-183X.2007.00348.x
- 357 Bruce, R. A., Weber, M. A., Volkman, R. A., Oya, M., Emmons, E. B., Kim, Y., & Narayanan, N. S.
- 358 (2021). Experience-related enhancements in striatal temporal encoding. *The European Journal of* 359 *Neuroscience*, 54(3), 5063–5074. https://doi.org/10.1111/ejn.15344
- Buhusi, C. V., & Meck, W. H. (2005). What makes us tick? Functional and neural mechanisms of interval
 timing. *Nature Reviews. Neuroscience*, 6(10), 755–765. https://doi.org/10.1038/nrn1764
- 362 Cai, R., Zhang, Y., Simmering, J. E., Schultz, J. L., Li, Y., Fernandez-Carasa, I., Consiglio, A., Raya, A.,
- 363 Polgreen, P. M., Narayanan, N. S., Yuan, Y., Chen, Z., Su, W., Han, Y., Zhao, C., Gao, L., Ji, X.,
- 364 Welsh, M. J., & Liu, L. (2019). Enhancing glycolysis attenuates Parkinson's disease progression
- in models and clinical databases. *The Journal of Clinical Investigation*, *129*(10), 4539–4549.
- 366 https://doi.org/10.1172/JCI129987
- 367 Dauer, W., & Przedborski, S. (2003). Parkinson's Disease: Mechanisms and Models. *Neuron*, *39*(6), 889–
 368 909. https://doi.org/10.1016/S0896-6273(03)00568-3
- Emmons, E., Tunes-Chiuffa, G., Choi, J., Bruce, R. A., Weber, M. A., Kim, Y., & Narayanan, N. S.
- 370 (2020). Temporal Learning Among Prefrontal and Striatal Ensembles. *Cerebral Cortex*
- 371 *Communications*, *1*(1), tgaa058. https://doi.org/10.1093/texcom/tgaa058
- Franklin, K. B. J., & Paxinos, G. (2008). *The mouse brain in stereotaxic coordinates* (Compact 3. ed).
 Elsevier Academic Press.
- 374 Gros, P., Wang, X., Guan, J., Lang, A. E., Austin, P. C., Welk, B., Visanji, N. P., & Marras, C. (2021).
- 375 Exposure to Phosphoglycerate Kinase 1 Activators and Incidence of Parkinson's Disease.

- 376 *Movement Disorders: Official Journal of the Movement Disorder Society*, 36(10), 2419–2425.
- 377 https://doi.org/10.1002/mds.28712
- 378 Gür, E., Duyan, Y. A., Arkan, S., Karson, A., & Balcı, F. (2020). Interval timing deficits and their
- neurobiological correlates in aging mice. *Neurobiology of Aging*, *90*, 33–42.
- 380 https://doi.org/10.1016/j.neurobiolaging.2020.02.021
- 381 Kim, Y.-C., Han, S.-W., Alberico, S. L., Ruggiero, R. N., De Corte, B., Chen, K.-H., & Narayanan, N. S.
- 382 (2017). Optogenetic Stimulation of Frontal D1 Neurons Compensates for Impaired Temporal
- 383 Control of Action in Dopamine-Depleted Mice. *Current Biology*, 27(1), 39–47.
- 384 https://doi.org/10.1016/j.cub.2016.11.029
- 385 Kim, Y.-C., & Narayanan, N. S. (2018). Prefrontal D1 Dopamine-Receptor Neurons and Delta Resonance
- 386 in Interval Timing. Cerebral Cortex (New York, N.Y.: 1991).
- 387 https://doi.org/10.1093/cercor/bhy083
- 388 Larson, T., Khadelwal, V., Weber, M. A., Leidinger, M. R., Meyerholz, D. K., Narayanan, N. S., &
- 389 Zhang, Q. (2022). *Mice expressing P301S mutant human tau have deficits in interval timing*

390 [Preprint]. Neuroscience. https://doi.org/10.1101/2022.04.04.487032

- 391 Narayanan, N. S., Land, B. B., Solder, J. E., Deisseroth, K., & DiLeone, R. J. (2012). Prefrontal D1
- 392 dopamine signaling is required for temporal control. *Proceedings of the National Academy of*393 *Sciences of the United States of America*, 109(50), 20726–20731.
- 394 https://doi.org/10.1073/pnas.1211258109
- 395 Nicolaus, M. L., Bergdall, V. K., Davis, I. C., & Hickman-Davis, J. M. (2016). Effect of Ventilated
- Caging on Water Intake and Loss in 4 Strains of Laboratory Mice. *Journal of the American Association for Laboratory Animal Science: JAALAS*, 55(5), 525–533.
- 398 Parker, K. L., Chen, K.-H., Kingyon, J. R., Cavanagh, J. F., & Naryanan, N. S. (2015). Medial frontal ~4
- Hz activity in humans and rodents is attenuated in PD patients and in rodents with cortical
- 400 dopamine depletion. *Journal of Neurophysiology*, jn.00412.2015.
- 401 https://doi.org/10.1152/jn.00412.2015

- 402 Sasane, R., Bartels, A., Field, M., Sierra, M. I., Duvvuri, S., Gray, D. L., Pin, S. S., Renger, J. J., & Stone,
- 403 D. J. (2021, April 6). Parkinson disease among patients treated for benign prostatic hyperplasia
- 404 *with αl adrenergic receptor antagonists*. American Society for Clinical Investigation.
- 405 https://doi.org/10.1172/JCI145112
- 406 Saxena, U. (2012). Bioenergetics failure in neurodegenerative diseases: Back to the future. *Expert*
- 407 *Opinion on Therapeutic Targets*, *16*(4), 351–354. https://doi.org/10.1517/14728222.2012.664135
- 408 Schultz, J. L., Brinker, A. N., Xu, J., Ernst, S. E., Tayyari, F., Rauckhorst, A. J., Liu, L., Uc, E. Y.,
- 409 Taylor, E. B., Simmering, J. E., Magnotta, V. A., Welsh, M. J., & Narayanan, N. S. (2022). A
- 410 pilot to assess target engagement of terazosin in Parkinson's disease. *Parkinsonism & Related*
- 411 *Disorders*, 94, 79–83. https://doi.org/10.1016/j.parkreldis.2021.11.022
- 412 Simmering, J. E., Welsh, M. J., Liu, L., Narayanan, N. S., & Pottegård, A. (2021). Association of
- 413 Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease. *JAMA*
- 414 *Neurology*. https://doi.org/10.1001/jamaneurol.2020.5157
- 415 Singh, A., Cole, R. C., Espinoza, A. I., Evans, A., Cao, S., Cavanagh, J. F., & Narayanan, N. S. (2021).
- 416 Timing variability and midfrontal ~4 Hz rhythms correlate with cognition in Parkinson's disease.
- 417 *NPJ Parkinson's Disease*, 7(1), 14. https://doi.org/10.1038/s41531-021-00158-x
- Thiele, S. L., Warre, R., & Nash, J. E. (2012). Development of a unilaterally-lesioned 6-OHDA mouse
 model of Parkinson's disease. *Journal of Visualized Experiments: JoVE*, 60, 3234.
- 420 https://doi.org/10.3791/3234
- 421 Torres, E. M., & Dunnett, S. B. (2012). 6-OHDA Lesion Models of Parkinson's Disease in the Rat. In E.
- 422 L. Lane & S. B. Dunnett (Eds.), *Animal Models of Movement Disorders: Volume I* (pp. 267–279).
 423 Humana Press. https://doi.org/10.1007/978-1-61779-298-4_13
- 424 Tosun, T., Gür, E., & Balci, F. (2016). Mice plan decision strategies based on previously learned time
- 425 intervals, locations, and probabilities. *Proceedings of the National Academy of Sciences*, 113(3),
- 426 787–792. https://doi.org/10.1073/pnas.1518316113

- 427 Wellstead, P., & Cloutier, M. (2011). An energy systems approach to Parkinson's disease. *WIREs Systems*
- 428 *Biology and Medicine*, *3*(1), 1–6. https://doi.org/10.1002/wsbm.107

430 FIGURES







442 Figure 2: Interval timing variability improves in VTA dopamine-depleted mice treated with

443 **terazosin. a**) Cumulative distribution function of switch times. **b**) Switch time coefficient of variability

444 (CV) and c) mean switch time. Data from 10 VTA Vehicle mice treated with dimethyl sulfoxide (DMSO;

445 in black), 8 VTA 6-hydroxydopamine (6-OHDA) mice treated with DMSO (in red), and 11 VTA 6-

446 OHDA mice treated with terazosin (TZ; in green). Each dot represents a single mouse, and the horizontal

line represents the median value. All data presented are approximately 16 days post-surgery and

448 normalized according to pre-surgical behavior. * p < 0.05.



451 Figure 3: VTA tyrosine hydroxylase (TH) fluorescence levels correlate with interval timing 452 coefficient of variability. a) Representative histological images of TH fluorescence (red) from VTA 453 Vehicle mice treated with dimethyl sulfoxide (DMSO; left), VTA 6-hydroxydopamine (6-OHDA) mice 454 treated with DMSO (middle), and VTA 6-OHDA mice treated with terazosin (TZ; right). b) VTA TH 455 fluorescence (in arbitrary units; AU) from 10 VTA Vehicle mice treated with DMSO (in black), 8 VTA 6-OHDA mice treated with DMSO (in red), and 11 VTA 6-OHDA mice treated with terazosin (in green). * 456 457 p < 0.05. Each dot represents a single mouse, and the horizontal line represents the median value. c) In VTA Vehicle and VTA 6-OHDA mice treated with DMSO, the percent change in coefficient of 458

- 459 variability (CV) relative to presurgical baseline is strongly correlated with VTA TH fluorescence (red and
- 460 black line). The relationship between VTA 6-OHDA and mice treated with terazosin is shown in green.



462

463 Figure 4: Fraction of Parkinson's disease patients remaining dementia free in the Truven Database.

464 Kaplan-Meier plot of 754 matched pairs of men aged 40 or older diagnosed with Parkinson's disease (PD)

465 and newly started on terazosin, alfuzosin, or doxazosin (green) or tamsulosin (red). The red and green

466 lines denote cumulative incidence of PD patients remaining dementia free, and the shaded areas denote

467 95% CI.

469 Supplemental

470

471 **Table S1**: Cohort Summary Measures Before and After Matching. Values reported are median

and inner quartile range for continuous variables or count and percent for binary variables. SMD

is the standardized mean difference or Cohen's *d*, a measure of effect size. Balance was obtained

474 (absolute value of SMD ≤ 0.1) on nearly all measures included in the propensity score model or

the disease duration.

	Before Matchin	g	•	After Matching		
Variable	$\begin{array}{c} \text{TZ/DZ/AZ} \\ (n = 875) \end{array}$	Tamsulosin $(n = 4,756)$	SMD	TZ/DZ/AZ	Tamsulosin	SMD
Demographics and Timing	••••	••••	•			
Age (years)	72	74	-0.08	72	72	0.01
	(63, 80)	(64, 81)		(63, 80)	(62, 81)	
RX Start Year	2003	2004	-0.02	2004	2004	0.01
	(2001, 2006)	(2001, 2008)		(2001, 2006)	(2002, 2008)	
Lookback (years)	3.8	4.8	-0.26	4.3	3.9	0.19
-	(2.2, 6.4)	(2.7, 7.8)		(2.5, 6.8)	(2.3, 6.0)	
Follow-Up (years)	1.8	2.0	-0.01	2.0	1.9	0.00
	(0.9, 4.1)	(0.9, 2.8)		(0.9, 4.2)	(0.9, 4.1)	
PD Disease Duration (years)	2.35	2.74	-0.18	2.57	2.47	0.10
	(1.53, 3.99)	(1.72, 4.60)		(1.68, 4.25)	(1.66, 3.97)	
Baseline Healthcare Utilization						
Inpatient Visits Per Year	0.14	0.35	-0.10	0.25	0.13	-0.13
-	(0.00, 1.34)	(0.00, 1.67)		(0.00, 1.41)	(0.00, 1.48)	
Outpatient Visits Per Year	17	17	-0.01	17	16	0.01
_	(10, 27)	(10, 27)		(11, 28)	(9, 27)	
Mean Number of Unique DX	0.35	0.31	0.05	0.31	0.36	-0.08
	(0.20, 0.62)	(0.17, 0.57)		(0.19, 0.56)	(0.21, 0.60)	
Outpatient DX Code Incidence	22	25	-0.10	23	22	0.00
	(14, 38)	(15, 42)		(14, 39)	(12, 38)	
Elixhauser Comorbidities						
Alcohol Abuse	12	117	-0.07	12	13	-0.01
	(1.4%)	(2.5%)		(1.6%)	(1.7%)	
Anemia	219	1,204	-0.01	201	177	0.07
	(25.0%)	(25.3%)		(26.7%)	(23.5%)	
Blood Loss	18	130	-0.04	16	15	0.01
	(2.1%)	(2.7%)		(2.1%)	(2.0%)	
Heart Failure	156	923	-0.04	138	144	-0.02
	(17.8%)	(19.4%)		(18.3%)	(19.1%)	
Coagulopathy	50	309	-0.03	46	32	0.09
	(5.7%)	(6.5%)		(6.1%)	(4.2%)	
Depression	143	841	-0.06	127	106	0.08
	(15.3%)	(17.7%)		(16.8%)	(14.1%)	
Diabetes W/O Complications	312	1,545	0.07	287	247	0.11
	(35.7%)	(32.5%)		(38.1%)	(32.8%)	
Diabetes W/ Complications	146	752	0.02	134	103	0.11
	(16.7%)	(15.8%)		(17.8%)	(13.7%)	
Drug Abuse	8	81	-0.06	6	19	-0.14
	(0.9%)	(1.7%)		(0.8%)	(2.5%)	
Fluid/Electrolyte Disorders	160	993	-0.06	147	138	0.03
	(18.3%)	(20.9%0		(19.5%)	(18.3%)	
HIV	3	7	0.05	3	1	0.05
	(0.3%)	(0.1%)		(0.4%)	(0.1%)	
HTN W/O Complications	623	3,310	0.04	555	528	0.08
	(71.2%)	(69.6%)		(73.6%)	(70.0%)	
HTN W/ Complications	169	875	0.02	159	134	0.08
	(19.3%)	(18.4%)		(21.1%)	(17.8%)	
Hypothyroidism	97	641	-0.07	95	97	-0.01

	$(11 \ 10\%)$	(13.5%)		(12.6%)	(12.0%)	
Linn Directo	(11.170)	(13.570)	0.00	(12.070)	(12.970)	0.05
Liver Disease	38	210	0.00	30	29	0.05
	(4.5%)	(4.4%)	0.02	(4.8%)	(3.8%)	0.04
Lymphoma	20	94	0.02	20	13	0.06
	(2.3%)	(2.0%)		(2.7%)	(1.7%)	
Metastatic Cancer	14	120	-0.06	14	18	-0.04
	(1.6%)	(2.5%)		(1.9%)	(2.4%)	
Other Neurological Disorders	626	3,788	-0.20	548	511	0.11
	(71.5%)	(79.6%)		(72.7%)	(67.8%)	
Obesity	45	381	-0.11	44	33	0.07
	(5.1%)	(8.0%)		(5.8%)	(4.4%)	
Paralysis	39	267	-0.05	36	29	0.05
	(4.5%)	(5.6%)		(4.8%)	(3.8%)	
Pulmonary/Circ Disorders	38	244	-0.04	35	42	-0.04
	(4.3%)	(5.1%)		(4.6%)	(5.6%)	
Psychoses	94	568	-0.04	89	81	0.03
	(10.7%)	(11.9%0		(11.8%)	(10.7%)	
Peptic Ulcer Disease	2	22	-0.04	2	3	-0.02
1 I	(0.2%)	(0.5%)		(0.3%)	(0.4%)	
COPD	256	1.536	-0.07	226	220	0.02
	(29.3%)	(32.3%)		(30.0%)	(29.2%)	
Peripheral Vascular Disease	205	1 329	-0.10	193	179	0.04
i emplicial vascular Discuse	(23.4%)	(27.9%)	0.10	(25.6%)	(23.7%)	0.04
Renal Failure	124	507	0.11	117	108	0.03
Renarrandic	(14.2%)	(10.7%)	0.11	(15.5%)	(14.3%)	0.05
Phoumatoid Arthritic	(14.270)	(10.770)	0.12	(13.570)	(14.370)	0.00
Kileumatolu Artiintis	(5,0%)	(8.6%)	-0.15	(5, 20%)	(5, 20%)	0.00
Calid Transm	(3.0%)	(0.0%)	0.00	(3.3%)	(3.5%)	0.01
Solid Tullior	(17.40)	(20.8%)	-0.09	(17.20)	133 (17.69/)	-0.01
VII D	(17.4%)	(20.8%)	0.12	(17.2%)	(17.0%)	0.04
Valvular Disease	1/6	1,193	-0.12	170	158	0.04
	(20.1%)	(25.1%)	0.10	(22.5%)	(21.0%)	0.02
Weight Loss	67	501	-0.10	57	64	-0.03
	(7.7%)	(10.5%)		(7.6%)	(8.5%)	
Prescribing Specific Consideration	S					
Indications						
	- 1			1		
PSA Measurement Taken	411	1,998	0.10	348	343	0.01
	(47.0%)	(42.0%)		(46.2%)	(45.5%)	
Abnormal PSA	109	721	-0.08	95	103	-0.03
	(12.5%)	(15.2%)		(12.6%)	(13.7%)	
Slow Urinary Stream	25	139	0.00	23	19	0.03
	(2.9%)	(2.9%)		(3.1%)	(2.5%)	
Uroflow Study	89	424	0.04	84	62	0.10
	(10.2%)	(8.9%)		(11.1%)	(8.2%)	
Cystometrogram	29	118	0.05	25	21	0.03
5 6	(3.3%)	(2.5%)		(3.3%)	(2.8%)	
Diagnosis of BPH	365	2.043	-0.03	323	305	0.05
	(41.7%)	(43.0%)		(42.8%)	(40.5%)	
Adverse Event Risks						I
Orthostatic Hypotension	28	276	-0.12	27	35	-0.05
Oraiostatic Hypotension	(3.2%)	(5.8%)	0.12	(3.6%)	(4.6%)	0.05
Other Hypotension	45	375	-0.10	41	35	-0.04
outer Hypotension	(5.1%)	(7.9%)	0.10	(5.4%)	(4.6%)	0.04
	(3.170)	(1.270)		(3.7/0)	(4.070)	